Radiation and immunotherapy before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 2 or 3 non-small cell lung cancer that the doctor thinks can be removed with surgery.
- You have not had any treatment for this cancer yet.
- You are between 18 and 75 years old.
- You are in good overall health (able to care for yourself, with normal blood and organ function).
- You do not have an autoimmune disease or active hepatitis, HIV, or tuberculosis.
- You do not have a specific gene change (EGFR mutation or ALK fusion) in your cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests using immunotherapy before surgery or radiation for non-small cell lung cancer. It looks at how safe and effective this approach is and how it affects survival.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
This trial tests a combination of targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib) given before surgery for people with a certain type of lung cancer that has not spread too far. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.